The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Prognostic Utility of Cell Cycle Progression Score in Men With Prostate Cancer After Primary External Beam Radiation Therapy
Open accessAbstract
Purpose The cell cycle progression (CCP) score, a prognostic RNA signature based on the average expression level of 31 CCP genes, has been shown to predict biochemical recurrence (BCR) after prostatectomy and prostate cancer specific mortality in men undergoing observation. However, the value of the CCP score in men who received primary external beam radiation therapy (EBRT) is untested. Methods and Materials The CCP score was derived retrospectively from diagnostic biopsy specimens of men diagnosed with prostate cancer from 1991 to 2006 (n=141). All patients were treated with definitive EBRT; approximately half of the cohort was African-American. Outcome was time from EBRT to BCR using the Phoenix definition. Median follow-up for patients without BCR was 4.8 years. Association with outcome was evaluated by CoxPH survival analysis and likelihood ratio tests. Results Of 141 patients, 19 (13%) had BCR. The median CCP score for patient samples was 0.12. In univariable analysis, CCP score significantly predicted BCR (p-value = 0.0017). The hazard ratio (HR) for BCR was 2.55 for a one-unit increase in CCP score (equivalent to a doubling of gene expression). In a multivariable analysis with Gleason score, PSA, percent positive cores, and androgen deprivation therapy, the HR for CCP remained significant (p-value = 0.034), indicating that CCP provides prognostic information that is not provided by standard clinical parameters. With 10-year censoring, the CCP score was associated with prostate cancer specific mortality (p-value = 0.013). There was no evidence for interaction between CCP and any clinical variable, including ethnicity. Conclusions Among men treated with EBRT, the CCP score significantly predicated outcome and provided greater prognostic information than was available with clinical parameters. If validated in a larger cohort, CCP score could identify high-risk men undergoing EBRT who may need more aggressive therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Pencina, M. J., D' Agostino, R. B., D' Agostino, R. B., & Vasan, R. S. (2008) · Statistics in Medicine · doi:10.1002/sim.2929 · Cited by 6,493
Cited by
Prostate Cancer, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology
Mohler, J. L., Antonarakis, E. S., Armstrong, A. J., D’Amico, A. V., Davis, B. J., Dorff, T., Eastham, J. A., Enke, C. A., Farrington, T. A., Higano, C. S., et al. (2019) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2019.0023 · Cited by 1,532
PSA and beyond: alternative prostate cancer biomarkers
Saini, S. (2016) · Cellular Oncology · doi:10.1007/s13402-016-0268-6 · Cited by 295
Epstein, J. I., Amin, M. B., Fine, S. W., Algaba, F., Aron, M., Baydar, D. E., Beltran, A. L., Brimo, F., Cheville, J. C., Colecchia, M., et al. (2021) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2020-0015-ra · Cited by 280
Genomic Markers in Prostate Cancer Decision Making
Cucchiara, V., Cooperberg, M. R., Dall’Era, M., Lin, D. W., Montorsi, F., Schalken, J. A., & Evans, C. P. (2018) · European Urology · doi:10.1016/j.eururo.2017.10.036 · Cited by 269
on behalf of the Transatlantic Prostate Group, Cuzick, J., Stone, S., Fisher, G., Yang, Z. H., North, B. V., Berney, D. M., Beltran, L., Greenberg, D., Møller, H., et al. (2015) · British Journal of Cancer · doi:10.1038/bjc.2015.223 · Cited by 155
Self-citation
Metadata
- Authors
- Freedland, S. J., Gerber, L., Reid, J., Welbourn, W., Tikishvili, E., Park, J., Younus, A., Gutin, A., Sangale, Z., Lanchbury, J. S., Salama, J. K., & Stone, S.
- Venue
- International Journal of Radiation Oncology*Biology*Physics
- Publisher
- Elsevier BV
- Published
- 2013-08
- Volume
- 86
- Issue
- 5
- Pages
- 848-853
- ISSN
- 0360-3016 (ISSN-L)
- OpenAlex
- W2009101549
- Cited by
- 184
- References
- 1
- FWCI
- 16.32
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Prognostic Utility of Cell Cycle Progression Score in Men With Prostate Cancer After Primary External Beam Radiation Therapy. https://app.cochat.ai/papers/10.1016/j.ijrobp.2013.04.043
- The paper
- Freedland, S. J., Gerber, L., Reid, J., Welbourn, W., Tikishvili, E., Park, J., Younus, A., Gutin, A., Sangale, Z., Lanchbury, J. S., Salama, J. K., & Stone, S. (2013). Prognostic Utility of Cell Cycle Progression Score in Men With Prostate Cancer After Primary External Beam Radiation Therapy. International Journal of Radiation Oncology*Biology*Physics. https://doi.org/10.1016/j.ijrobp.2013.04.043
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.